Concerns over adverse reactions, blood clots, reports of breakthrough COVID cases in vaccinated people, vaccine contamination and scrutiny over CEO pay have plagued the roll-out of the company’s COVID vaccine.
It’s been a bumpy ride for Johnson & Johnson’s (J&J) COVID vaccine rollout.
At the beginning of the month, the vaccine maker had to throw out 15 million doses of its vaccine after they were contaminated with AstraZeneca vaccine ingredients at an unapproved manufacturing plant. The setback contributed to last week’s announcement that the company won’t be able to deliver on its promise of 24 million additional doses of its one-shot vaccine by the end of April.
Those weren’t the only negative headlines. Last week, J&J vaccine sites in four states had to shut down after reports of adverse reactions. There also were multiple reports of COVID breakthrough cases in people who received the vaccine, marketed under its subsidiary, Janssen.
J&J is on notice regarding investigations by European and U.S. regulators for reports of blood clots in individuals who received the vaccine.
And today, the company faced more backlash from investors after its CEO was awarded a 17% pay raise while billions are being paid out for the company’s role in the nation’s opioid epidemic.
Here’s a breakdown of the five reasons J&J is having a very bad month:
1. Vaccination sites shut down in four states after more than 45 people suffer adverse reactions.
2. Reports of COVID in people fully vaccinated with J&J’s vaccine continue to mount.
3. U.S. and European regulators are reviewing cases of blood clots in people who received J&J’s vaccine.
4. J&J vaccine output dropped by 85% after 15 million doses were contaminated with AstraZeneca ingredients.
5. Critics take shots at J&J over CEO’s $30 million pay package while the company pays out billions for its role in the opioid epidemic.
Read the full story here: Source: 5 Reasons Johnson & Johnson Is Having a Very Bad Month • Children’s Health Defense